BrainsWay published new results from a peer-reviewed pilot study evaluating Deep TMS in patients with co-occurring major depressive disorder and early-stage Alzheimer’s disease, reporting an 83.3% response rate and 50% remission rate.
Published
Signal category
Research & Knowledge
Quote
“New results from a peer-reviewed pilot study evaluated Deep TMS in patients with co-occurring major depressive disorder (MDD) and early-stage Alzheimer’s disease.”
— BrainsWay team
Company
BrainsWay
Global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
- Industry
- Medical Equipment Manufacturing
- Location
- Burlington, US
- Company size
- 145 employees
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Founded 2003